Study Summary
This trial is studying how well FASN inhibitor TVB-2640, paclitaxel, and trastuzumab work in treating patients with HER2 positive breast cancer that has spread to other places in the body (metastatic).
- HER2-positive Breast Cancer
- Stage III Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIA Breast Cancer
- Breast Cancer
- Stage IV Breast Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 3 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)
1 of 2
Cohort B (TVB-2640, trastuzumab, endocrine therapy)
1 of 2
Experimental Treatment
80 Total Participants · 2 Treatment Groups
Primary Treatment: FASN Inhibitor TVB-2640 · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any precedent studies regarding the effectiveness of FASN Inhibitor TVB-2640?
"Currently, there are 1219 clinical trials actively researching FASN Inhibitor TVB-2640. Of these live studies, 322 have reached Phase 3. Primarily based in Seattle, Washington, the expansive research on this inhibitor is being conducted across a staggering 69515 sites around the world." - Anonymous Online Contributor
Is recruitment for this investigation still open to participants?
"Affirmative. Clinicaltrials.gov attests to this medical research's current recruitment status, which began on September 25th 2017 and was recently updated on May 31st 2022. The investigation requires 80 participants across 3 sites of study." - Anonymous Online Contributor
To what extent has enrollment in this experiment grown?
"Affirmative. The information available on clinicaltrials.gov demonstrates that the study, which was initially advertised on September 25th 2017 is actively recruiting patients. A total of 80 participants are required to be recruited from 3 separate medical facilities." - Anonymous Online Contributor
In what circumstances is TVB-2640, a FASN inhibitor, usually administered?
"FASN Inhibitor TVB-2640 is an effective treatment option for those with metastatic bladder cancer, inflammatory breast cancer (ibc), or acquired immunodeficiency syndrome." - Anonymous Online Contributor
What potential risks are associated with FASN Inhibitor TVB-2640?
"Due to the lack of efficacy-confirming data, FASN Inhibitor TVB-2640 was given a safety rating of 2 on our team's scale. This is because it has only been tested in Phase 2 trials thus far." - Anonymous Online Contributor